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Abstract 
Background and Aims: Ustekinumab is a monoclonal antibody that binds with high 
affinity to the p40 subunit of human interleukin 12 (IL12 and IL23) that has been 
approved for treatment of patients with moderate to severe Crohn’s disease (CD). 
However, there are few data on its pharmacokinetic properties or the relationship 
between drug exposure levels and patient response. We collected data from 2 phase 3 
induction studies and 1 maintenance study to determine ustekinumab’s pharmacokinetic 
features, relationship between exposure and response, and optimal serum 
concentrations for efficacy. 
Methods: We collected data on serum concentrations of ustekinumab and efficacy from 
induction studies of patients with moderate to severe CD given ustekinumab for 
8 weeks following a single intravenous dose (either 130 mg or approximately 6 mg/kg). 
We collected the same data from a maintenance study of patients with a response to 
ustekinumab in the induction study who then received subcutaneous injections (90 mg) 
every 8 or 12 weeks for 44 weeks. At week 44 of the maintenance study (52 weeks after 
treatment began) patients were evaluated for the primary endpoint of clinical remission 
(defined as a CD activity index score below 150 points), endoscopic markers of efficacy, 
and serum level of C-reactive protein. Ustekinumab concentration data were 
categorized into quartiles and relationships between exposure and response were 
assessed. Optimal concentration cut-off values were evaluated using receiver operating 
characteristic curve analysis. 
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Results: Serum concentrations of ustekinumab over time were proportional to dose and 
did not differ significantly between the induction studies. In the maintenance study, 
ustekinumab concentration reached the steady state by the second maintenance dose; 
the median trough concentration was approximately 3-fold higher in patients given 
ustekinumab at 8-week intervals compared with 12-week intervals. Ustekinumab serum 
concentrations associated with rates of clinical remission and endoscopic efficacy 
endpoints, correlated inversely with level of C-reactive protein, and did not associate 
with use of immunomodulators. Trough concentrations of ustekinumab of 0.8 (or even 
up to 1.4 µg/mL) or greater were associated with maintenance of clinical remission in a 
higher proportion of patients than patients with lower trough concentrations.  
Conclusions: In an analysis of data from phase 3 studies of patients with moderate to 
severe CD, we found serum concentrations of ustekinumab to be proportional to dose 
and associate with treatment efficacy. Concentrations of ustekinumab did not seem to 
be affected by co-treatment with immunomodulators. Clinicaltrials.gov no: 
NCT01369329 (UNITI 1), NCT01369342 (UNITI 2), and NCT01369355 (IM UNITI) 
Keywords: UNITI trials, inflammatory bowel disease treatment, IBD, anti-IL12/23 
 
 
INTRODUCTION 
Crohn’s disease (CD) is a chronic idiopathic inflammatory bowel disease (IBD) that can 
affect any portion of the intestinal tract1-3 and is histologically characterized by 
granulomas, fissuring ulceration, submucosal fibrosis, and transmural gut infiltration of 
lymphocytes and macrophages.4, 5 Biologic agents have transformed the treatment of 
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CD, with tumor necrosis factor (TNF) antagonists at the forefront,6-11 most often used in 
patients who do not respond or are intolerant to treatment with corticosteroids and/or 
oral immunosuppressants.12, 13 However, a large proportion of patients with CD either 
do not respond to treatment with TNF antagonists or only have a transient response that 
later requires dose escalation or switching to another therapy.6, 10, 14-18 Thus, there is a 
significant medical need for novel, safe, and effective therapies for moderately to 
severely active CD, particularly in patients who do not respond, lose response, or are 
intolerant to treatment with TNF antagonists. 
 In nonclinical studies, the proinflammatory cytokines interleukin 12 (IL12) and 
interleukin 23 (IL23) have been implicated in the pathophysiology of CD with multiple 
lines of evidence suggesting that CD is mediated by Th1 and/or Th17 cells.19-26 
Ustekinumab, a fully human immunoglobulin G1 kappa monoclonal antibody that binds 
with high affinity to the p40 subunit of human IL12 and IL23, has recently been 
approved for the treatment of moderately to severely active CD in adults. Ustekinumab 
prevents IL12 and IL23 bioactivity by preventing their interaction with their cell surface 
receptor protein IL12Rβ1. Through this mechanism of action, ustekinumab effectively 
neutralizes IL12 (Th1)- and IL23 (Th17)-mediated cellular responses. Evidence for the 
efficacy of ustekinumab in CD was first supported by the results of a proof of concept 
Phase 2a study of ustekinumab in patients who had moderate-to-severe CD27 and then 
in the CERTIFI Phase 2b study of ustekinumab in patients with CD who did not respond 
or were intolerant to TNF antagonist therapy.28 These Phase 2 studies formed the basis 
for the Phase 3 program of ustekinumab treatment for patients with CD, which consisted 
of 2 induction studies (UNITI-1 and UNITI-2) that led into a single randomized 
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withdrawal maintenance study (IM-UNITI), results for which have been previously 
reported.29 The UNITI-1 trial included patients who met the criteria for primary or 
secondary nonresponse to TNF antagonists or had unacceptable side effects, while the 
UNITI-2 trial included patients in whom conventional therapy failed or unacceptable side 
effects occurred. 
There is currently a lack of ustekinumab pharmacokinetics (PK) and 
exposure-response (ER) data in CD from large, randomized, controlled trials. These 
data are critical to therapeutic drug monitoring, which is an important area of focus for 
gastroenterologists treating IBD. Here, we report on ustekinumab PK and ER 
relationships using data derived from these previously reported Phase 3 induction and 
maintenance studies in CD (3 randomized, placebo-controlled, double-blind trials), 
which comprised the largest cohort to date of ustekinumab-treated patients with CD.29 
Understanding the PK and association of ustekinumab exposure to efficacy outcomes 
and identification of optimal concentration thresholds may ultimately further the ability to 
individualize treatment of patients with CD. 
 
MATERIALS AND METHODS 
Patients and Study Design 
Detailed design and clinical results of the UNITI-1, UNITI-2, and IM-UNITI trials have 
been reported.29 Briefly, all three trials were Phase 3, randomized, double-blind, 
placebo-controlled, parallel-group, multicenter studies. UNITI-1 and UNITI-2 were 
8-week induction studies in patients with moderately to severely active CD. Clinical 
responders to ustekinumab at Week 8 of induction treatment from UNITI-1 and UNITI-2 
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comprised the primary analysis population in IM-UNITI, a 44-week randomized-
withdrawal maintenance study. The Institutional Review Board or ethics committee at 
each study site approved the protocols, and all patients provided written informed 
consent. All authors had access to the study data and have reviewed and approved the 
final manuscript. 
 The UNITI-1 trial studied patients with moderate-severe CD (CD Activity Index 
[CDAI] score of 220 to 450) who previously did not respond, lost response, or were 
intolerant to TNF antagonists (N=741). These patients were randomized to receive a 
single intravenous (IV) induction dose of either placebo, a fixed ustekinumab dose of 
130 mg, or a tiered dose of ustekinumab approximating 6 mg/kg (260 mg [weight 
≤55 kg], 390 mg [weight >55 kg and ≤85 kg], or 520 mg [weight >85 kg]), referred to 
hereafter as ~6 mg/kg. Of the 741 randomized patients, 740 were included in the PK/ER 
analyses.  
 In the UNITI-2 trial, patients with CDAI scores of 220 to 450 who had not 
responded to or were intolerant to conventional therapy (corticosteroids or 
immunomodulators) but not TNF antagonists (N=628) were randomized to receive the 
same dosage regimens as the UNITI-1 trial. Of the 628 randomized patients, 68% were 
naïve to prior TNF antagonists, and 626 of the 628 were included in the PK/ER 
analyses. 
 In UNITI-1 and UNITI-2 all patients were evaluated at Week 6 (induction) for the 
primary endpoint of clinical response, defined as a reduction from baseline in the CDAI 
score of ≥100 points; although, patients with a baseline CDAI score of ≥220 to ≤248 
were considered to be in clinical response if a CDAI score of <150 was attained. The 
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first major secondary endpoint of clinical remission at Week 8 was defined as a CDAI 
score of <150 points. 
 In the IM-UNITI trial, patients in the primary efficacy population were responders 
to ustekinumab induction in either UNITI-1 or UNITI-2 (N=397) and were randomized 
1:1:1 at Week 0 of that study to receive subcutaneous (SC) placebo or 1 of 
2 ustekinumab maintenance regimens (ustekinumab 90 mg SC every 12 weeks [q12w] 
through Week 36 [ie at Weeks 0, 12, 24 and 36] or ustekinumab 90 mg SC every 
8 weeks [q8w] through Week 40 [ie at Weeks 0, 8, 16, 24, 32, and 40]). Of the 397 
randomized patients, 387 were included in the PK/ER analysis. At Week 44 of that 
study, 52 weeks after induction Week 0, patients were evaluated for the primary 
endpoint of clinical remission, defined as a CDAI score of <150 points. ER was also 
assessed at Week 24 as it was the only concurrent trough time point for both the q8w 
and q12w ustekinumab regimens. A patient disposition diagram is shown in 
Supplemental Figure 1 and a study design schematic is shown in 
Supplemental Figure 2. 
 
Study Evaluations and Analyses 
Serum ustekinumab concentrations (hereafter referred to as ustekinumab 
concentration[s]) were measured in blood samples collected at scheduled visits through 
Week 8 of UNITI-1 and UNITI-2 and through Week 44 of IM-UNITI 
(Supplemental Table 1) using a validated electrochemiluminescent immunoassay 
(ECLIA) method on the Meso Scale Discovery (MSD®) platform (Gaithersburg, MD, 
USA). The lowest quantifiable concentration in a sample for the ECLIA method using 
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the MSD platform was 0.1688 µg/mL (data on file). Because steady state was invariably 
attained by Week 24 of the maintenance study for both ustekinumab maintenance 
regimens, average trough concentrations through Week 44 were obtained by computing 
the arithmetic mean of patients observed trough concentrations (q12w: Weeks 24 and 
36; q8w: Weeks 24, 32, and 40). The relationship between clinical remission and trough 
ustekinumab concentration quartiles in maintenance were also examined at Week 24 of 
IM-UNITI, the timepoint where q8w and q12w shared a preadministration trough. 
 To assess disease activity, CDAI scores were used to determine clinical 
response and clinical remission, as defined above. Additionally, endoscopic endpoints 
were assessed at Week 44 (maintenance) using the Simple Endoscopic Score for 
Crohn's Disease (SES-CD)30 in the subset of patients participating in the endoscopy 
substudy. Briefly, the scoring of the video endoscopies for the SES-CD was performed 
by a single reader at a central facility who was blinded to treatment group. Patients with 
a baseline SES-CD score ≥3 (indicating mucosal ulceration in at least one segment) 
were included in the endoscopy analyses.  
The association between ustekinumab concentration and serum C-reactive 
protein (CRP) was also evaluated. CRP was measured with a validated high-sensitivity 
CRP immunonephelometry assay using the Siemens BNII Nephelometer (Covance 
Central Laboratory Services) with a lower limit of quantification of 0.2 mg/L. 
 Antibodies to ustekinumab were assessed at baseline and Week 6 of the 
induction study, and at Weeks 0, 12, 24, 36, and 44 of the maintenance study. These 
analyses were performed using a validated and drug-tolerant ECLIA on the MSD 
platform (Gaithersburg, MD), in which ustekinumab was used to capture and detect 
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induced immune responses to ustekinumab. The assay can detect anti-ustekinumab 
antibodies in the presence of up to 100 µg/mL of ustekinumab. Patients were classified 
as positive if antibodies were detected at any time in their serum sample. 
 
Statistical Analysis 
All ustekinumab concentration data were summarized for each treatment group using 
descriptive statistics that were calculated at each sampling timepoint. Missing 
ustekinumab concentration data were not imputed, and the data handling rules for the 
efficacy variables were previously described in Feagan et al 2016.29 The relationships 
between ustekinumab concentration and clinical remission and CRP concentration were 
assessed. A one-sided Cochrane-Armitage trend test was used to evaluate the 
presence of a trend in the proportion of patients with a clinical efficacy outcome across 
ustekinumab concentration quartiles. For comparisons of variables across concentration 
quartiles, a nonparametric one-way analysis of variance (ANOVA) based on the median 
score was used for continuous and ordinal variables, while a Fisher’s exact test was 
used for categorical variables. Optimal cutpoints of ustekinumab concentration 
associated with efficacy outcomes were determined using receiver operating 
characteristic (ROC) curve analysis. All statistical testing was performed at the 
.05 significance level. 
RESULTS 
Baseline patient characteristics 
Among the 1366 UNITI-1 and UNITI-2 patients included in the PK/ER analyses 
(Supplemental Figure 1), baseline demographic and other characteristics were 
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representative of an adult population with moderately to severely active CD and were 
balanced between the treatment groups (Supplemental Table 2 and Table 1). 
 
Pharmacokinetics 
All induction dose groups had peak median ustekinumab concentrations at 
Week 0 (induction), 1 hour after IV infusion. Ustekinumab concentrations were 
proportional to dose and similar between UNITI-1 and UNITI-2 (Figure 1).  
 In the UNITI-1 trial median peak ustekinumab concentrations 1-hour post infusion 
at Week 0 (induction) were 43.6 µg/mL and 129.1 µg/mL for the 130 mg and ~6 mg/kg 
dose groups, respectively. At Week 8, median ustekinumab concentrations were 
2.1 µg/mL and 6.4 µg/mL for the 130 mg and ~6 mg/kg dose groups, respectively.  
 In UNITI-2, median peak ustekinumab concentrations 1-hour post infusion at 
Week 0 (induction) were 39.8 µg/mL and 124.4 µg/mL for the 130 mg and ~6 mg/kg 
dose groups, respectively. At Week 8, median ustekinumab concentrations were 
2.0 µg/mL and 6.3 µg/mL for the 130 mg and ~6 mg/kg dose groups, respectively.  
 Among IV ustekinumab responders randomized to placebo maintenance, median 
ustekinumab concentrations were undetectable by Week 12 in recipients of 130 mg and 
by Week 16 in those that had received the ~6 mg/kg induction dose (Figure 2). In 
contrast, median ustekinumab concentrations were maintained above detectable limits 
through Week 44 of IM-UNITI among patients randomized to either ustekinumab 
maintenance regimen (Figure 2). Ustekinumab concentrations reached steady state by 
the second SC maintenance dose (ie 16 weeks after induction [Week 8 of IM-UNITI] for 
q8w and 20 weeks after induction [Week 12 of IM-UNITI] for q12w). Median 
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pre-administration ustekinumab concentrations were consistent through Week 44 for 
both 90 mg q8w (ranging from 2.0 µg/mL to 2.2 µg/mL at IM-UNITI Weeks 8, 16, 24, 32, 
and 40) and 90 mg q12w (ranging from 0.6 µg/mL to 0.8 µg/mL at IM-UNITI Weeks 12, 
24, and 36) (Figure 2). Thus, median trough concentrations in the ustekinumab 
90 mg q8w group were approximately 3-fold greater than in the 90 mg q12w group.  
 Serum ustekinumab concentrations were similar between patients who were on 
azathioprine (AZA), 6-mercaptopurine (6-MP), or methotrexate (MTX), compared with 
those who were not on these drugs (Supplemental Figure 3). 
 
Exposure-response: ustekinumab concentrations and efficacy outcomes 
To assess the relationship between efficacy and systemic exposure to ustekinumab, 
concentrations of ustekinumab at induction Week 8 and maintenance Weeks 24, as well 
as average trough concentrations through Week 44 were categorized into quartile 
groups. The proportions of patients in clinical remission (CDAI score <150 points) were 
summarized by these quartiles.  
 In both induction trials, combining the 130 mg and ~6 mg/kg dose groups, higher 
remission rates were observed in the 2 higher ustekinumab concentration quartiles at 
Week 8, compared with the 2 lower quartiles (Figure 3A and B) though this pattern was 
more apparent in UNITI-2. This trend was significant in both UNITI-1 (P = .039) and 
UNITI-2 (P = .007). Of note, when examining ER within the approved ~6 mg/kg dose, 
the remission rate remained largely unchanged in UNITI-2 with only a ~1% increase in 
remission rate from the 3rd to the 4th quartile despite concentration doubling 
(Supplemental Figure 4B). Although the ER across the quartiles was not as clear in the 
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UNITI-1 data, the remission rates were not higher in the 3rd or 4th quartile when 
compared to the 2nd quartile, which had substantially lower concentrations 
(Supplemental Figure 4A). Taken together, these data do not suggest a higher induction 
dose would have resulted in higher remission rates at Week 8 across the population. 
 In the maintenance study, greater proportions of patients were in clinical 
remission at Week 24 in the higher ustekinumab concentration quartiles (Figure 3C). 
Clinical remission was seen in 55.3% and 70.8% of patients in the two lower quartiles, 
while the two higher quartiles saw remission rates of 77.1% and 81.3% (P = .002). In 
the lowest quartile, where the lowest remission rates were observed, a substantial 
majority of patients were receiving the q12w regimen. 
 When maintenance ER was examined by dosing regimen (q12w and q8w), the 
proportion of patients in remission was incrementally higher from the 2nd through the 
4th quartile for the q12w treatment quartiles (Figure 3D, P = .084). By contrast, the top 
three quartiles of the q8w treatment all had comparable remission rates around 80% 
(Figure 3E, P = .006). Average steady-state trough concentrations were similarly 
associated with remission at Week 44 (maintenance primary endpoint; Supplemental 
Figure 5, P = .003). With respect to endoscopic endpoints at Week 44 of maintenance, 
greater proportions of patients achieved a reduction in the SES-CD score of 3 points or 
more with increasing ustekinumab concentration (Figure 4A, P = .038). Further, greater 
endoscopic response (Figure 4B, P = .006) and remission rates (Figure 4C, P = .054) 
were observed in the top 3 concentration quartiles compared to the first quartile. In all 
cases, the lowest serum ustekinumab concentration quartile (≤0.5 µg/mL) had notably 
lower proportions achieving the endoscopic endpoints. 
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 To assess the relationship between ustekinumab exposure and CRP 
concentration, the distribution of the CRP concentration was also compared across the 
ustekinumab concentration quartiles. A trend toward lower CRP concentration with 
increasing ustekinumab concentration was observed at induction Week 8 
(Supplemental Figure 6A and B, P < .001). Similar patterns were observed during 
maintenance with steady-state ustekinumab concentration and CRP at Week 24 
(P < .001, Supplemental Figure 6C) and Week 44 (P = .008; Supplemental Figure 6D). 
In addition, a greater proportion of patients had normalized CRP at higher serum 
ustekinumab concentration (P < .001, Supplemental Figure 7). However, as seen in 
Table 1, baseline CRP concentrations were significantly higher to begin with in the 
lower concentration quartiles (and were also much lower to begin with in the higher 
quartiles; Table 1). Additionally, a positive correlation was observed between CRP 
concentration at baseline and at end of induction (Week 8: correlation coefficient r = .58, 
P < .001) as well as during maintenance (Week 24: r = .63, P < .001; Week 44: r = .68, 
P < .001). To correct for this, CRP ER analyses were limited to patients with baseline 
CRP between 3 mg/L and 10 mg/L, a range chosen to eliminate outliers but still include 
enough patients to analyze (as most patients are in this range). Interestingly, no 
statistically significant trend was observed in this subgroup analysis suggesting that 
patients with higher baseline CRP may be driving the association noted in the complete 
dataset. 
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Estimation of optimal ustekinumab concentration targets 
To identify a concentration of ustekinumab that distinguishes patients with and without 
clinical remission, ROC curves were generated for remission endpoints during both the 
induction and maintenance treatment periods. Using serum ustekinumab concentration 
at Week 8 to correlate with remission at Week 8, the ROC analysis identified a cut-off of 
3.3 µg/mL with an area under the curve (AUC) of 0.57 (P = .001); sensitivity and 
specificity were 0.63 and 0.52, respectively (Figure 5A). With respect to maintenance, 
ROC analyses performed for the combined q8w and q12w regimens resulted in 
statistically significant AUCs (95% CI = 0.64 [0.56 - 0.70], P = .003 using trough 
concentration at Week 24 versus remission at Week 24 [Table 2, Figure 5B]; and 
95% CI = 0.62 [0.54 - 0.69], P = .011 using average trough concentration versus 
remission at Week 44 [Table 2, Figure 5C]). Similar results were obtained using trough 
concentration at Week 40 versus remission at Week 44 for the q8w regimen only 
(Table 2). ROC analysis using only the q12w data (data not shown) resulted in AUCs 
that were not statistically significant; thus, a cut-off could not be determined based on 
only this subgroup. Overall, steady-state serum ustekinumab trough concentration 
targets for clinical remission during maintenance ranged from 0.8 to 1.4 µg/mL. 
 
Immunogenicity 
A total of 1154 treated patients who received at least 1 dose of ustekinumab during 
induction or maintenance had appropriate samples for antibody testing. Of those, 
27 patients (2.3%) were positive for antibodies to ustekinumab during at least one 
timepoint through one year. Many of these patients were only positive at a single 
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timepoint and then had subsequent negative antibody results. Additionally, 20 of the 27 
patients had titers at or below 1:800. Seventeen of the 27 (63.0%) were positive for 
neutralizing antibodies. Of note, in subjects randomized to maintenance, induction 
responders who continued to receive ustekinumab maintenance therapy had a lower 
incidence of anti-ustekinumab antibodies (2.7% [7/263]) compared with the 
5.3% (7/133) who did not receive continuous ustekinumab maintenance (ie induction 
responders who went on placebo during maintenance). Among treated patients, the 
proportion positive for antibodies to ustekinumab was 1.9% (7/375) among those who 
received concomitant immunomodulators and 2.6% (20/779) among patients who did 
not. Median serum ustekinumab concentrations were generally lower in the few patients 
who were positive for antibodies. For example, at Week 24, median steady-state serum 
ustekinumab concentration was 0.3 µg/mL in the 5 patients positive for antibodies to 
ustekinumab compared with 1.1 µg/mL in the 186 patients who were negative. None of 
the patients who were positive for antibodies to ustekinumab had injection-site, 
serum-sickness-like, or anaphylaxis reactions. 
 
Safety 
Select aggregate adverse events (AEs) that occurred during these trials have been 
previously published.29 No consistent relationship was observed between ustekinumab 
concentration and the incidence of infections, serious infections, or serious AEs during 
either induction or maintenance (Supplemental Table 3). 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
DISCUSSION 
Ustekinumab, which was approved for CD in the US, Canada, and EU in 2016, targets 
the IL12 and IL23 inflammatory pathways and has a well-established safety profile in 
clinical trials and clinical practice since its first approval for moderate to severe plaque 
psoriasis in 2009.31-33 In the present analyses of the UNITI-1 and UNITI-2 CD induction 
studies and the IM-UNITI maintenance study, we evaluated the PK of ustekinumab in 
patients with moderately to severely active CD and provide the first detailed 
assessments of associations between ustekinumab concentration and efficacy 
outcomes. This is the most comprehensive PK and ER evaluation of ustekinumab in 
patients with CD to date. Understanding ustekinumab PK characteristics and the 
relationship between efficacy outcomes and ustekinumab concentrations is important 
for prescribers to optimize efficacy with ustekinumab therapy.  
 These analyses demonstrated that ustekinumab exhibits dose-proportional PK 
behavior with IV induction doses of 130 mg and ~6 mg/kg that was similar in patients 
who did not respond to, lost response to, or were intolerant to treatment with TNF 
antagonists (UNITI-1 population) as well as in patients who did not respond or were 
intolerant to conventional therapy and who were predominantly naïve to TNF 
antagonists (UNITI-2 population). These findings suggest that the clearance of 
ustekinumab does not vary with dose or study patient population. Therefore, the better 
efficacy seen in TNF-antagonist-naïve patients compared to TNF-antagonist-failure 
patients does not seem to be attributable to differences in ustekinumab exposure. The 
observed dose proportional profile of ustekinumab allows for the prediction of the impact 
of dose changes on systemic exposure.  
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 Strong positive associations were seen between ustekinumab concentration and 
clinical efficacy outcomes in induction. With the approved ~6 mg/kg dose, remission 
rates appear to have peaked in the higher concentration quartiles. However, in both 
induction studies, patients in the lowest quartile demonstrated notably lower rates of 
remission at Week 8 suggesting these patients with high drug clearance and baseline 
disease activity are a population that would be appropriate to consider further induction 
dose intensification, eg, in future studies. 
Similarly, maintenance ER analysis showed strong positive correlations between 
steady-state trough ustekinumab concentrations (first attained at the time of the second 
90 mg SC dose) and remission with both maintenance regimens (90 mg SC q12w and 
q8w) individually, as well as when the data from the regimens were combined. Within 
the q8w regimen, efficacy appears to have peaked from the 2nd concentration quartile 
suggesting that an efficacy plateau was reached at the exposures attained by most 
patients. The patients in the lowest quartile (≤0.9 µg/mL) with this regimen achieved a 
substantially lower clinical remission rate. Data within the 90 mg q12w group was 
consistent with this observation as the highest remission rates occurred within the last 
quartile (>1.2 µg/mL) in the q12w group and was comparable with remission rates in 
patients who fell within or above the 2nd quartile (>0.9 µg/mL) in the q8w group. 
Endoscopic outcomes at Week 44 were also notably greater in the 3 higher quartiles 
(>0.5 µg/mL) than in the first quartile (≤0.5 µg/mL).  
Based on the ROC analyses, steady-state concentration cut-offs ranging 
between 0.8 to 1.4 µg/mL were associated with greater clinical remission during 
maintenance, corroborating the quartile analysis. The range of these target 
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concentrations illustrate that there is some heterogeneity in applying precise level 
“targets” to individual patients, even when they are valid across a population. In terms of 
implications for clinical practice, this appears to support shortening the interval to q8w in 
q12w patients that are not in remission and have trough levels below this range (in 
regions where q12w is an approved regimen). Patients on 90 mg q8w in this same 
circumstance would be a potential population in which to evaluate further dose 
intensification. Ideally, a future prospective study would examine if better clinical 
outcomes are achieved by interval shortening (eg to 6 or 4 weeks) in order to attain 
higher trough concentrations above the 0.8 to 1.4 µg/mL target.  
 In contrast with the above findings about ustekinumab concentration thresholds 
for optimal efficacy, Battat et al34 recently reported that trough levels above 4.5 µg/mL 
were associated with biomarker reduction and endoscopic response in a 
TNF antagonist-refractory population. Importantly, the study that identified this relatively 
high trough level was limited by a small sample size (N=62), the use of SC 
administration for induction, and the fact that the majority of the patients (approximately 
75%) received ustekinumab 90 mg every 4 weeks as opposed to the approved q8w or 
q12w regimens. This is relevant because levels are invariably higher at 4 weeks, 
specifically, >2-fold higher than at 8 weeks given ustekinumab’s ~3-week half-life. In 
addition, potential differences in the assays used to measure ustekinumab may have 
contributed to the apparent discrepancy in the proposed concentration threshold. Of the 
factors evaluated, body weight, serum albumin, and disease severity indicators (CDAI, 
fecal markers, CRP) were associated with differences in ustekinumab concentration. 
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These findings are consistent with reports of the PK characteristics of some other 
monoclonal antibodies used in the treatment of inflammatory bowel disease.35, 36  
 The incidence of antibodies to ustekinumab through 1 year on treatment was 
2.3% (using a drug-tolerant assay), indicating that ustekinumab has low 
immunogenicity. In contrast, the rates of anti-drug antibodies with similarly drug-tolerant 
assays with TNF antagonists are substantially higher with rates of 39.8% for 
adalimumab37 and 51% for infliximab38 in recent reports using drug-tolerant assays. 
Although lower serum concentrations were observed among those who had antibodies 
to ustekinumab, there was no demonstrable effect of immunogenicity on efficacy; 
however, with such a low proportion of patients exhibiting anti-drug antibodies, such 
associations cannot be fully assessed. Importantly, the incidence of anti-drug antibodies 
was slightly higher among those who were randomized to placebo maintenance (5.7%), 
suggesting that intermittent therapy is a risk factor for immunogenicity, as has been 
seen with other biologics.39 
 In contrast to the experience with TNF antagonists,7, 40 there was no significant 
impact of AZA, 6-MP, or MTX on serum ustekinumab concentration and 
immunogenicity. For TNF antagonists such as infliximab, the effects of these drugs on 
PK is hypothesized to be the result of decreased immunogenicity (ie, less tendency to 
develop ADAs), a possible shared mechanism of apoptosis,7 or a decreased expression 
of receptors important for monoclonal antibody disposition (for example, Fcγ receptors 
on monocytes thereby affecting a monoclonal antibody’s PK).41-43 In the case of 
ustekinumab treatment in patients with CD, the low incidence of anti-ustekinumab 
antibodies may explain the lack of impact of AZA, 6-MP, or MTX on ustekinumab levels, 
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supporting immunogenicity as the primary driver of the impact of such drugs on 
antibody concentration. In contrast to other biologics, because of the apparent lack of 
need for an immunomodulator, it would seem appropriate to utilize ustekinumab as 
monotherapy in CD rather than combination therapy. 
 In addition to the association of systemic ustekinumab exposure and clinical 
efficacy variables, we found that ustekinumab concentration was inversely related to 
CRP concentration and positively correlated with normalization of CRP during both 
induction and maintenance. While this points to the possibility that RP concentration 
could provide some indication of the effect of treatment, it is difficult to interpret due to 
the observation that post-treatment CRP is highly correlated with pre-treatment CRP. 
This implies that drug clearance (and therefore ustekinumab concentration) is 
associated with baseline CRP. This is presumably a function of the higher underlying 
disease activity, for which CRP is a marker, rather than the CRP molecule itself. Thus, 
pre-treatment CRP may be a potential predictor of ustekinumab concentration in 
patients receiving ustekinumab. 
 Regarding safety, we did not observe an association between ustekinumab 
concentration and infections, serious infections, or serious adverse events. This finding 
suggests that the occurrence of these safety events is not attributable to the levels of 
ustekinumab exposure attained with the dose regimens evaluated in these Phase 3 
studies. 
 It is important to acknowledge that these analyses had some limitations. First, the 
number of patients in the maintenance study decreased over time, which may have 
implications for the maintenance ER analysis. However, ER analysis using 
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model-predicted ustekinumab concentration data yielded similar results. Second, the 
ustekinumab concentration cut-offs obtained from the ROC analyses were based on 
statistically significant but modest AUC and specificity values which suggest that factors 
other than serum ustekinumab concentrations (such as markers of inflammatory 
burden) may need to be evaluated to improve the ability to predict efficacy. In addition, 
the relatively low specificity associated with the identified thresholds implies that the 
likelihood of false-positive results (ie, low concentrations occurring in responders) may 
be high and that additional clinical judgment should be employed if patients appear to 
maintain efficacy despite low concentrations. On the other hand, the relatively higher 
sensitivity values associated with these thresholds assure treating physicians that levels 
above these targets are likely adequate to achieve, or maintain, efficacy. Nevertheless, 
the predictive ability of drug concentration versus efficacy is consistent with those 
observed from the ROC analyses of TNF antagonists in IBD.44-46 Finally, while the 
incidence of antibodies to ustekinumab was low and no impact was observed on 
efficacy and safety, these results should be interpreted with caution due to the limited 
number of patients with anti-ustekinumab antibodies in these analyses. 
 In conclusion, a positive association between ustekinumab concentrations and 
efficacy outcomes in patients with CD was confirmed during both induction (UNITI-1 
and -2) and maintenance (IM-UNITI) studies. The ER findings support the use of both 
the approved weight-based induction regimen (~6 mg/kg) and the q8w maintenance 
regimen for the treatment of CD, although a number of patients on the q12w 
maintenance regimen also attained the ustekinumab concentration cut-off associated 
with efficacy outcomes. Importantly, ustekinumab concentrations were not influenced by 
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immunomodulators, in marked contrast to infliximab7, suggesting ustekinumab can be 
used as monotherapy and there may be no benefit or need for combination therapy. 
While additional studies will be required to determine whether proactive therapeutic 
drug monitoring to target levels improves long-term CD outcomes, these results from 
the largest cohort of patients with CD treated with ustekinumab to date (1369 total 
patients and ~100 on each maintenance regimen) can provide important guidance for 
treating moderately to severely active CD with ustekinumab. 
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Figures 
Figure 1. Median serum ustekinumab concentrations illustrating dose proportionality 
over time during the induction studies UNITI-1 and UNITI-2. 
 
Figure 2. Median serum ustekinumab concentrations over time after induction with a 
dose of 130 mg (A) or ~6mg/kg (B) and through the maintenance study IM-UNITI. The 
patients in the placebo groups in both A and B received an IV induction dose of 
ustekinumab only and were on placebo treatment during maintenance. I, induction; 
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IV, intravenous; M, maintenance; q8w, every 8 weeks; q12w, every 12 weeks; 
SC, subcutaneous. 
 
Figure 3. Proportions of patients achieving clinical remission by serum ustekinumab 
concentration quartiles at Week 8 in the UNITI-1 (A) and UNITI-2 (B) induction studies, 
at Week 24 (C) in the IM-UNITI maintenance study, and at Week 24 in the q12w (D) 
and q8w (E) doses in the IM-UNITI maintenance study. Patients in the placebo group 
received an IV induction dose of ustekinumab only and were on placebo treatment 
during maintenance. IV, intravenous; N, number of patients; Q, quartile; q8w, every 8 
weeks; q12w, every 12 weeks; SC, subcutaneous. 
 
Figure 4. Proportions of patients achieving endoscopic endpoints by serum 
ustekinumab concentration quartiles at Week 44 in the IM-UNITI maintenance study. 
Reduction in the SES-CD score of ≥3 points (A), endoscopic response (B), and 
endoscopic remission (C). Average trough concentrations were obtained by computing 
the arithmetic mean of the observed trough concentration for each patient (q12w: 
Week 24, Week 36; q8w: Week 24, Week 32, and Week 40) to reflect average 
exposure at steady state. N, number of patients; Q, quartile; SES-CD, Simple 
Endoscopic Score for Crohn's Disease. 
 
Figure 5. Receiver operating characteristic curve analysis of optimal serum 
ustekinumab thresholds associated with clinical remission at Week 8 (A) of the 
combined UNITI-1 and UNITI-2 induction studies, and at Week 24 (B) and Week 44 (C) 
of the IM-UNITI maintenance study. Average trough concentrations were obtained by 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
33 
 
computing the arithmetic mean of the observed trough concentration for each patient 
(q12w: Week 24, Week 36; q8w: Week 24, Week 32, and Week 40) to reflect average 
exposure at steady state. AUC, area under the curve. 
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Tables 
Table 1: Comparison of Baseline Patient Characteristics by Serum Ustekinumab Concentration Quartiles at Week 8 of 
Induction and at Week 24 of Maintenance Among Patients Treated with Ustekinumab in the UNITI-1, UNITI-2, and 
IM-UNITI Studies. 
Characteristic  
Baseline values at Induction Week 0 
Median values       
Ustekinumab concentration at Week 8 (Induction) 
 All Q1 Q2 Q3 Q4 P-valuea 
N 701 175 175 176 175 
 
Age (yrs) 36.0  32.0 36.0 37.0 41.0 .004 
Body weight (kg) 68.5 66.4 66.8 69.9 72.3 .064 
CDAIb 302.0 324.0 305.0 294.5 292.0 .017 
Disease duration from time of diagnosis 
(yrs) 
8.4 6.9 9.1 7.8 10.2 .135 
Fecal calprotectin (µg/kg) 473.4 727.8 473.4 374.3 242.3 <.001 
Fecal lactoferrin (µg/mL) 88.2 202.4 102.6 61.6 39.3 <.001 
Albumin (g/dL) 3.6 3.2 3.6 3.7 3.8 <.001 
CRP (mg/L) 8.4 22.5 9.2 5.6 5.3 <.001 
 
      
Proportions 
Male Gender, % 43.1 48.6 44.6 38.6 40.6 .245 
Antibody-to-ustekinumab status 
(positive), % 
3.1 5.7 0.6 2.9 3.4 .042 
History of TNF antagonist use, % 64.9 69.1 65.1 65.3 60.0 .359 
Concomitant immunomodulator use at 
baseline (Y), % 
33.4 33.1 33.7 34.1 32.6 .993 
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Corticosteroid use at baseline (Y), % 36.0 38.3 34.9 39.2 31.4 .411 
Ustekinumab concentration at Week 24 (Maintenance) 
 All Q1 Q2 Q3 Q4 P-valuea 
N 191 47 48 48 48 
 
Age (yrs) 35.0  39.0 31.0 35.0 37.5 .050 
Body weight (kg) 67.6 70.5 67.3 64.3 70.9 .318 
CDAIb 299.0 307.0 310.5 292.5 300.0 .377 
Disease duration from time of diagnosis 
(yrs) 
7.0 6.7 8.1 7.0 7.7 .876 
Fecal calprotectin 523.3 595.9 550.0 523.5 318.1 .026 
Fecal lactoferrin 104.6 172.5 128.4 107.8 36.9 .058 
Albumin (g/dL) 3.6 3.4 3.6 3.8 3.9 <.001 
CRP (mg/L) 8.0 19.4 10.2 6.9 2.6 <.001 
 
      
Proportions 
      
Male Gender, % 44.0 55.3 41.7 33.3 45.8 .187 
Antibody-to-ustekinumab status 
(positive), % 
2.6 6.4 2.1 0.0 2.1 .227 
History of TNF antagonist use, % 53.9 59.6 45.8 60.4 50.0 .398 
Immunomodulator use at baseline (Y), % 39.3 46.8 35.4 41.7 33.3 .532 
Corticosteroid use at baseline (Y), % 34.0 31.9 31.3 41.7 31.3 .658 
aFor comparisons of variables across ustekinumab concentration quartiles, a nonparametric one-way ANOVA based on the median score was 
used for continuous and ordinal variables, while a Fisher’s exact test was used for categorical variables. 
bCDAI scores range from approximately 0 to 600, with higher scores indicating worse disease and a 50-point change indicating the minimal 
clinically important difference. 
ANOVA, analysis of variance; CDAI, Crohn’s Disease Activity Index; CRP, C-reactive protein; N, number of patients; Q, quartile; TNF, tumor 
necrosis factor; Y, yes; Yrs, years. 
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Table 2: Receiver Operating Characteristic Analysis Metrics for the Relationship 
Between Ustekinumab Concentration and Efficacy During the IM-UNITI Study. 
 
PK Measure Efficacy Endpoint ROC metric Value 
    
Trough ustekinumab 
concentration at Week 24 
(Combined q8w and q12w) 
Remission at Week 24 AUC  
(95% CI; P-value) 
0.64  
(0.56 - 0.70; P = .003) 
  Sensitivity (%) 67 
  Specificity (%) 60 
  Threshold (µg/mL) 0.82 
    
Average trough ustekinumab 
concentrationa 
(Combined q8w and q12w) 
Remission at Week 44 AUC  
(95% CI; P-value) 
0.62  
(0.54 - 0.69; P = .011) 
  Sensitivity (%) 73 
  Specificity (%) 56 
  Threshold (µg/mL) 0.80 
    
Trough ustekinumab 
concentration at Week 40 
(q8w only) 
Remission at Week 44 AUC  
(95% CI; P-value) 
0.66  
(0.54 - 0.76; P = .047) 
  Sensitivity (%) 82 
  Specificity (%) 47 
  Threshold (µg/mL) 1.35 
aAverage of trough ustekinumab concentrations at Weeks 24, 32 and 40 for q8w and at Weeks 24 and 36 
for q12w. 
AUC, area under the curve; CI, confidence interval; PK, pharmacokinetic; q8w, every 8 weeks; q12w, 
every 12 weeks; ROC, receiver operating characteristic. 
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Supplemental Figures 
 
Supplemental Figure 1. Patient disposition throughout the UNITI-1, UNITI-2 and 
IM-UNITI studies among the 1366 patients who had serum ustekinumab concentration 
and efficacy outcome data suitable for analysis. ER, exposure-response; 
IV, intravenous; N, number of patients; PK, pharmacokinetic; q8w, every 8 weeks; 
q12w, every 12 weeks; SC, subcutaneous. 
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Supplemental Figure 2. Study design and flow for the UNITI-1, UNITI-2 and IM-UNITI 
studies (A) and in randomized and nonrandomized patients in IM-UNITI (B). 
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IV, intravenous; LTE, long-term extension; N, number of patients; q8w, every 8 weeks; 
q12w, every 12 weeks; SC, subcutaneous; TNF, tumor necrosis factor. 
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Supplemental Figure 3. Median serum ustekinumab concentrations over time through 
the maintenance study IM-UNITI in those receiving or not receiving concomitant 
immunomodulators. 6-MP, 6-mercaptopurine; AZA, azathioprine; I, induction; 
IV, intravenous; M, maintenance; MTX, methotrexate; q8w, every 8 weeks; 
SC, subcutaneous. 
 
 
Supplemental Figure 4. Proportions of patients achieving clinical remission by serum 
ustekinumab concentration quartiles at Week 8 in the ~6 mg/kg dose in the UNITI-1 (A) 
and UNITI-2 (B) induction studies. N, number of patients; Q, quartile. 
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Supplemental Figure 5. Proportions of patients achieving clinical remission by average 
trough serum ustekinumab concentration quartiles at Week 44 in the IM-UNITI 
maintenance study. Patients in the placebo group received an IV induction dose of 
ustekinumab only and were on placebo treatment during maintenance. Average trough 
concentrations were obtained by computing the arithmetic mean of the observed trough 
concentration for each patient (q12w: Week 24, Week 36; q8w: Week 24, Week 32, and 
Week 40) to reflect average exposure at steady state. IV, intravenous; N, number of 
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patients; Q, quartile; q8w, every 8 weeks; q12w, every 12 weeks; SC, subcutaneous. 
 
Supplemental Figure 6. Median C-reactive protein levels at Week 8 in the UNITI-1 (A) 
and UNITI-2 (B) induction studies and at Week 24 (C) and Week 44 (D) in the IM-UNITI 
maintenance study by serum ustekinumab concentration quartiles. In A and B, the 
quartiles represent the combined 130 mg and ~6 mg/kg induction treatments, and in C 
and D the quartiles represent the combined 90 mg SC q12w and q8w maintenance 
treatments. Patients in the placebo groups in C and D received an IV induction dose of 
ustekinumab only and were on placebo treatment during maintenance. Average trough 
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concentrations were obtained by computing the arithmetic mean of the observed trough 
concentration for each patient (q12w: Week 24, Week 36; q8w: Week 24, Week 32, and 
Week 40) to reflect average exposure at steady state. CRP, C-reactive protein; 
IV, intravenous; N, number of patients; Q, quartile; q8w, every 8 weeks; q12w, every 12 
weeks; SC, subcutaneous. 
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Supplemental Figure 7. Proportions of patients achieving normalized C-reactive 
protein by serum ustekinumab concentration quartiles at Week 8 in the UNITI-1 (A) and 
UNITI-2 (B) induction studies. The quartiles represent the combined 130 mg and 
~6 mg/kg induction treatments. CRP, C-reactive protein; N, number of patients; 
Q, quartile.  
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Supplemental Tables 
 
Supplemental Table 1: Pharmacokinetic Sampling Schematic for the UNITI-1, UNITI-2, and IM-UNITI Studies. 
 
 
Study 
 
0 
(I-0) 
 
3 
(I-3) 
 
6 
(I-6) 
8 
(I-8/ 
M-0) 
 
12 
(M-4) 
 
16 
(M-8) 
 
20 
(M-12) 
 
24 
(M-16) 
 
28 
(M-20) 
 
32 
(M-24) 
 
36 
(M-28) 
 
40 
(M-32) 
 
44 
(M-36) 
 
48 
(M-40) 
 
52 
(M-44) 
UNITI-1 
•a • • •b NA 
UNITI-2 
•a • • •b NA 
IM-UNITI NA •b,c • • • • • • • • • • • 
aSamples obtained both pre-administration and at 1 hour post-infusion. 
bSample at Week 0 of maintenance (M-0) is the same as sample at Week 8 of induction (I-8). 
cPatients who were nonresponders to placebo during an induction study (UNITI-1/UNITI-2) received IV ustekinumab 130 mg at M-0 (IM-UNITI) 
and had pre- and post-infusion samples at M-0. 
I, Induction; IV; intravenous; M, Maintenance; NA, Not applicable. 
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Supplemental Table 2: Baseline Patient Characteristics of the Patients in the UNITI-1, 
UNITI-2, and IM-UNITI Studies Included in the Pharmacokinetic/ Exposure-Response 
Analysis (N=1366). 
 
Characteristic Proportion 
Male gender 44.6% 
Concomitant azathioprine/6-mercaptopurine/methotrexate 33.1% 
Concomitant corticosteroid use 34.6% 
Prior TNF antagonist use 68.5% 
Characteristic Median (Range) 
Age, yrs 37.0 (18.0 – 77.0) 
Body weight, kg 68.8 (35.0 – 184.0) 
Disease duration, yrs 8.7 (0.1 – 52.4) 
CDAIa 305.0 (198.0 – 515.0) 
CRP, mg/L 9.1 (0.1 – 18.0) 
Fecal calprotectin, µg/kg 483.0 (11.8 – 16647.2) 
Fecal lactoferrin, µg/mL 90.9 (0.4 – 1002.3) 
Serum albumin, g/dL 3.6 (1.2 – 5.1) 
aCDAI scores range from approximately 0 to 600, with higher scores indicating worse disease and a 50-
point change indicating the minimal clinically important difference. 
CDAI, Crohn’s Disease Activity Index; CRP, C-reactive protein; N, number of patients; TNF, tumor 
necrosis factor; Yrs, years. 
 
Supplemental Table 3: Ustekinumab Concentrations and Selected Safety Events 
During the UNITI-1, UNITI-2, and IM-UNITI Studies. 
 
Induction: UNITI-1 and UNITI-2 
Safety Event Incidence through Week 8 
  
Placebo 
(N=452) 
Q1 
(N=175) 
Q2 
(N=175) 
Q3 
(N=176) 
Q4 
(N=175) 
Infections, (%) 23.5 21.1 21.7 22.7 20.6 
Serious Infections, (%) 1.3 3.4 0.0 1.7 0.6 
SAEs, (%) 6.0 8.0 4.6 2.8 1.7 
Serum ustekinumab concentration at Week 8 was used as the systemic exposure metric; Q1: ≤1.6 µg/mL, 
Q2: >1.6 to ≤3.5 µg/mL, Q3: >3.5 to ≤6.8 µg/mL, Q4: >6.8 µg/mL 
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Maintenance: IM-UNITI 
Safety Event Incidence through Week 44 
  
Placebo 
(N=131) 
Q1 
(N=48) 
Q2 
(N=48) 
Q3 
(N=48) 
Q4 
(N=48) 
Infections, (%) 67.2 58.3 43.8 66.7 58.3 
Serious Infections, (%) 3.1 8.3 2.1 2.1 4.2 
SAEs, (%) 21.4 12.5 14.6 4.2 12.5 
Average steady-state serum ustekinumab concentration was used as the systemic exposure metric; 
Q1: ≤0.5 µg/mL, Q2: >0.5 to ≤1.1 µg/mL, Q3: >1.1 to ≤2.3 µg/mL, Q4: >2.3 µg/mL 
N, number of patients; Q, quartile; SAE, serious adverse event. 
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